Comparison of IgA Levels in the Bronchoalveolar Lavage Fluid of Patients With and Without Antibiotic Therapy
NCT ID: NCT02912520
Last Updated: 2017-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2016-06-30
2017-04-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Airway Microbiome of Patients With Protracted Bacterial Bronchitis
NCT07255430
Innate Immune Response of Blood Cells in Patients With Pneumonia
NCT03231670
Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis
NCT00633191
Chronic Airway Disease, Mucus Rheology and Exacerbations
NCT04339270
Antibiotics in Chronic Obstructive Pulmonary Disease (COPD)
NCT00952861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with antibiotic therapy
Patients with antibiotic therapy for 2 weeks.
Anti-Bacterial Agents
administration of any antibiotic substance(s) over the course of 2 weeks
Patients without antibiotic therapy
Patients without any antibiotic therapy in the last 3 months.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-Bacterial Agents
administration of any antibiotic substance(s) over the course of 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* antibiotic therapy for 2 weeks OR no antibiotic therapy for at least 3 months
Exclusion Criteria
* pregnancy
* immunodeficiency
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oliver Robak
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oliver Robak, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hoogkamp-Korstanje JA, de Koning J, Heesemann J, Festen JJ, Houtman PM, van Oyen PL. Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy. Infection. 1992 Mar-Apr;20(2):53-7. doi: 10.1007/BF01711062.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ORV001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.